Stifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

TipRanksMay 20 21:05

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific

BusinesswireMay 20 15:05

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy From RBC Capital

TipRanksMay 17 05:27

Contineum Therapeutics (CTNM.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -3.55 dollars, previous value of -2.12 dollars.

Contineum Therapeutics (CTNM.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -3.55 dollars, previous value of -2.12 dollars.

Zhitong FinanceMay 16 17:20

Contineum Therapeutics | 10-Q: Quarterly report

SEC announcementMay 16 16:04 · Announcements

Contineum Therapeutics 1Q Loss/Shr $3.55 >CTNM

Contineum Therapeutics 1Q Loss/Shr $3.55 >CTNM

Dow JonesMay 16 15:06